Se connecter

Bibliographies thématiques / Novartis Campus

Sommaire

Articles de revues
Livres
Chapitres de livres

Littérature scientifique sur le sujet « Novartis Campus »

Auteur : Grafiati

Publié le 25 juillet 2024

Mis à jour le 31 juillet 2025

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Novartis Campus ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Novartis Campus"

1

Latagliata, Roberto, Isabella Capodanno, Maria Cristina Miggiano, et al. "Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study." Blood 138, Supplement 1 (2021): 3617. http://dx.doi.org/10.1182/blood-2021-151538.

Texte intégral

Résumé :

Abstract Introduction Treatment of chronic phase (CP) chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) proved to be almost equally effective in young and elderly patients. Three TKIs, imatinib (IM), dasatinib (DAS) and nilotinib (NIL), are approved for frontline therapy in Italy. Choice of frontline TKI is based on a combined evaluation of patient's characteristics and expectations, with age usually playing a prominent role. However, to date, few data are available on patterns of TKI selection in very elderly patients. Aim To analyse the use of frontline TKI therapy in a l

Styles APA, Harvard, Vancouver, ISO, etc.

2

Chiaretti, Sabina, Massimiliano Bonifacio, Roberta Agrippino, et al. "ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report." Blood 138, Supplement 1 (2021): 216. http://dx.doi.org/10.1182/blood-2021-150958.

Texte intégral

Résumé :

Abstract Introduction. The recent spread of the COVID-19 infection has represented an important challenge in the management of acute lymphoblastic leukemia (ALL) patients. Aims and methods. To investigate the incidence, features, source of contagion and outcome of patients with ALL who developed a COVID-19 infection, a survey was conducted among 34 hematology centers throughout Italy within the Campus ALL network. The period covered by the survey spanned from February 2020 to April 2021 and included 756 adult ALL patients actively followed during this time period. Results. Sixty-three of the 7

Styles APA, Harvard, Vancouver, ISO, etc.

3

Gugliotta, Gabriele, Mario Annunziata, Isabella Capodanno, et al. "Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study." Blood 136, Supplement 1 (2020): 45–46. http://dx.doi.org/10.1182/blood-2020-141077.

Texte intégral

Résumé :

INTRODUCTION: Frontline therapy with second generation (2G) tyrosine-kinase inhibitors (TKIs) in chronic phase (CP) chronic myeloid leukemia (CML) patients demonstrated higher efficacy as compared to imatinib, with less patients experiencing treatment failure and progression to advanced disease. However, limited information are currently available on the management and outcome of those CML pts not achieving an optimal response to first-line treatment with a 2G-TKI. AIM: To describe the clinical outcome of CP CML patients without an optimal response to a frontline 2G-TKI that switched to altern

Styles APA, Harvard, Vancouver, ISO, etc.

4

Tiribelli, Mario, Isabella Capodanno, Maria Cristina Miggiano, et al. "Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study." Blood 138, Supplement 1 (2021): 1487. http://dx.doi.org/10.1182/blood-2021-149780.

Texte intégral

Résumé :

Abstract Background Tyrosine kinase inhibitors (TKIs) revolutionized treatment of chronic myeloid leukemia (CML). However, the first months of therapy are crucial, as optimal response is defined as the achievement of molecular milestones at 3, 6 and 12 months (mo.) and as many toxicities, also causing a TKI switch, are more frequent in the 1st year. Methods To evaluate achievement of early molecular response (MR) and incidence of events leading to a TKI change during the 1st year of therapy, we retrospectively studied 1650 CP-CML patients diagnosed from 2012 and 2019 at 31 Hematology Centres a

Styles APA, Harvard, Vancouver, ISO, etc.

5

Zoller, Frank A., and Roman Boutellier. "Design principles for innovative workspaces to increase efficiency in pharmaceutical R&D: lessons learned from the Novartis campus." Drug Discovery Today 18, no. 7-8 (2013): 318–22. http://dx.doi.org/10.1016/j.drudis.2012.12.012.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Sciumè, Mariarita, Cristina Papayannidis, Antonio Curti, et al. "Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study." Blood 138, Supplement 1 (2021): 3408. http://dx.doi.org/10.1182/blood-2021-147325.

Texte intégral

Résumé :

Abstract Blinatumomab (Blina) and inotuzumab (InO) have improved the outcome of relapsed/refractory B-lymphoblastic leukemia (R/R B-ALL). However, many patients (pts) relapse after these treatments and little is known on their outcomes after recurrence and re-treatment with subsequent immunotherapy. We hereby describe the clinical characteristics and outcome of 71 pts with R/R B-ALL treated with both Blina and InO in any sequence - Blina/InO or InO/Blina - at different disease recurrences. At diagnosis, the median age was 34 years (15-64) and the male/female ratio was 1.6. Sixteen pts (22%) we

Styles APA, Harvard, Vancouver, ISO, etc.

7

Bonifacio, Massimiliano, Chiara Elena, Mariella D'Adda, et al. "Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations." Blood 136, Supplement 1 (2020): 43–44. http://dx.doi.org/10.1182/blood-2020-139826.

Texte intégral

Résumé :

Background. The Philadelphia (Ph) chromosome (chr.) is the hallmark of chronic myeloid leukemia (CML) and typically results from the reciprocal translocation t(9;22)(q34;11.2). Complex variant translocations (CVT) involving one or more additional chr. are identified in less than 5% of newly diagnosed CML. There are conflicting reports about the prognostic impact of CVT in the achievement of optimal response to tyrosine kinase inhibitor (TKI), and very few studies addressed the role of frontline treatment with imatinib or second generation (2G)-TKI in patients with CVT. Aims. To assess the resp

Styles APA, Harvard, Vancouver, ISO, etc.

8

Tiribelli, Mario, Roberto Latagliata, Massimo Breccia, et al. "Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the "Registro Italiano LMC & Campus CML"." Blood 136, Supplement 1 (2020): 35–36. http://dx.doi.org/10.1182/blood-2020-135972.

Texte intégral

Résumé :

Introduction : therapy of chronic phase (CP) chronic myeloid leukemia (CML) is based on tyrosine kinase inhibitors (TKIs) in virtually all patients. Three TKIs are approved for first-line therapy in Italy: imatinib and two second-generation (2G) TKIs, dasatinib and nilotinib. Choice of the front-line TKI is based on a combined evaluation of patient's and disease characteristics, age, risk, comorbidities and concomitant medications. Treating physician's preference and, in some cases, economic considerations, particularly after the advent of generic imatinib, may play a role in TKI selection. Ho

Styles APA, Harvard, Vancouver, ISO, etc.

9

Gentile, Massimo, Fortunato Morabito, Giovanni Del Poeta, et al. "External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study." Blood 134, Supplement_1 (2019): 4308. http://dx.doi.org/10.1182/blood-2019-126702.

Texte intégral

Résumé :

Novel therapies targeting BTK (ibrutinib), PI3Kδ (idelalisib) and BCL2 (venetoclax) are active in poor-risk chronic lymphocytic leukemia (CLL) and are widely administered to patients with relapsed/refractory (R/R)-CLL. Given the activity of ibrutinib in high-risk CLL patients, including those with del17p/TP53 mutation or germline IGHV genes, we assumed that this drug could diminish the prognostic utility of the CLL-IPI, because the outcome of patients with high- and very high-risk CLL-IPI scores may improve. Recently, Soumerai et al (Lancet Hematology, 2019) proposed a new risk score for overa

Styles APA, Harvard, Vancouver, ISO, etc.

10

Downton, Teesha, Emma Karlsen, Katharine Cuff, Euan Walpole, Fiona Simpson, and Elgene Lim. "Abstract OT2-10-05: HER2Pro: A Phase 1b dose de-escalation study of high dose prochlorperazine added to paclitaxel, trastuzumab and pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer." Cancer Research 83, no. 5_Supplement (2023): OT2–10–05—OT2–10–05. http://dx.doi.org/10.1158/1538-7445.sabcs22-ot2-10-05.

Texte intégral

Résumé :

Abstract HER2Pro: A Phase 1b dose de-escalation study of high dose prochlorperazine added to paclitaxel, trastuzumab and pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer Authors Teesha Downton1,2, Emma Karlsen1, Katharine Cuff3,4, Euan Walpole3,4, Fiona Simpson3,4, Elgene Lim1,2. Affiliations 1Garvan Institute of Medical Research, Darlinghurst NSW, Australia; 2School of Clinical Medicine, St Vincent’s Healthcare Clinical Campus, Faculty of Medicine and Health, University of New South Wales Sydney, Australia; 3Diamantina Institute, University of Queensland

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Livres sur le sujet "Novartis Campus"

1

(Basel, Switzerland) Novartis Campus. Fumihiko Maki: Novartis Campus - Square 3. Christoph Merian, 2010.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Ulrike, Jehle-Schulte Strathaus, and Architekturmuseum in Basel, eds. Novartis Campus, Forum 3: Diener, Federle, Wiederin. Architekturmuseum, 2005.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Herzog & de Meuron, ed. Novartis Campus - Asklepios 8: Herzog & de Meuron. Christoph Merian Verlag, 2015.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Ltd, SANAA, and Schweizerisches Architekturmuseum, eds. Novartis Campus--Fabrikstrasse 4: Sanaa/Sejima + Nishizawa : works by Walter Niedermayr : [im Zusammenhang mit der Ausstellung "Novartis Campus - Peter Märkli und SANAA/Walter Niedermayr", Schweizerisches Architekturmuseum, September 24 - November 26, 2006. Christoph Merian, 2006.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

1946-, Krischanitz Adolf, and Krischanitz und Frank Architekten, eds. Novartis Campus - Fabrikstrasse 16: Krischanitz, Krischanitz und Frank Architekten. C. Merian, 2008.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Ulrike, Jehle-Schulte Strathaus, and Schweizerisches Architekturmuseum, eds. Peter Märkli: Novartis Campus--Fabrikstrasse 6 : [im Zusammenhang mit der Ausstellung "Novartis Campus - Peter Märkli und SANAA / Walter Niedermayr", Schweizerisches Architekturmuseum, September 24 - November 26, 2006]. Schweizerisches Architekturmuseum, 2006.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Rahul Mehrotra - Novartis Campus Virchow 16. Christoph Merian, 2015.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Novartis Campus - Fabrikstrasse 22: David Chipperfield. Christoph Merian, 2011.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Novartis Campus - Fabrikstrasse 28: Tadao Ando. Merian Verlag, 2011.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Yoshio Taniguchi: Novartis Campus - Fabrikstrasse 10. Ch. Merian, 2010.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Chapitres de livres sur le sujet "Novartis Campus"

1

"Bürogebäude auf dem Novartis Campus in Basel." In Arbeitswelten. DETAIL, 2011. http://dx.doi.org/10.11129/detail.9783955530396.92.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

"NOVARTIS CAMPUS, EAST HANOVER, NEW JERSEY, UNITED STATES." In Transforming Landscapes. Birkhäuser, 2020. http://dx.doi.org/10.1515/9783035609974-018.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

"CAMPUS NOVARTIS, EAST HANOVER, NEW-JERSEY, ÉTATS-UNIS." In Territoires en projet. Birkhäuser, 2020. http://dx.doi.org/10.1515/9783035609981-018.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!